Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more
Hainan Honz Pharmaceutical Co (300086) - Total Assets
Latest total assets as of September 2025: CN¥1.88 Billion CNY
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) holds total assets worth CN¥1.88 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hainan Honz Pharmaceutical Co - Total Assets Trend (2007–2024)
This chart illustrates how Hainan Honz Pharmaceutical Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hainan Honz Pharmaceutical Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Hainan Honz Pharmaceutical Co's total assets of CN¥1.88 Billion consist of 22.4% current assets and 77.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.7% |
| Accounts Receivable | CN¥111.28 Million | 5.6% |
| Inventory | CN¥187.33 Million | 9.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥190.82 Million | 9.7% |
| Goodwill | CN¥13.50 Million | 0.7% |
Asset Composition Trend (2007–2024)
This chart illustrates how Hainan Honz Pharmaceutical Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Honz Pharmaceutical Co's current assets represent 22.4% of total assets in 2024, a decrease from 67.8% in 2007.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 42.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 9.7% of total assets.
Hainan Honz Pharmaceutical Co Competitors by Total Assets
Key competitors of Hainan Honz Pharmaceutical Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Hainan Honz Pharmaceutical Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hainan Honz Pharmaceutical Co generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hainan Honz Pharmaceutical Co is currently not profitable relative to its asset base.
Hainan Honz Pharmaceutical Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 1.10 | 1.22 |
| Quick Ratio | 0.31 | 0.63 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-151.19 Million | CN¥ 46.66 Million | CN¥ 128.20 Million |
Hainan Honz Pharmaceutical Co - Advanced Valuation Insights
This section examines the relationship between Hainan Honz Pharmaceutical Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.76 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -8.8% |
| Total Assets | CN¥1.98 Billion |
| Market Capitalization | $368.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Honz Pharmaceutical Co's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hainan Honz Pharmaceutical Co's assets decreased by 8.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hainan Honz Pharmaceutical Co (2007–2024)
The table below shows the annual total assets of Hainan Honz Pharmaceutical Co from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.98 Billion | -8.76% |
| 2023-12-31 | CN¥2.17 Billion | -5.37% |
| 2022-12-31 | CN¥2.29 Billion | -6.93% |
| 2021-12-31 | CN¥2.46 Billion | -5.93% |
| 2020-12-31 | CN¥2.61 Billion | +19.11% |
| 2019-12-31 | CN¥2.19 Billion | +0.64% |
| 2018-12-31 | CN¥2.18 Billion | -2.48% |
| 2017-12-31 | CN¥2.24 Billion | +2.12% |
| 2016-12-31 | CN¥2.19 Billion | +4.77% |
| 2015-12-31 | CN¥2.09 Billion | +8.45% |
| 2014-12-31 | CN¥1.93 Billion | +1.19% |
| 2013-12-31 | CN¥1.90 Billion | -3.26% |
| 2012-12-31 | CN¥1.97 Billion | +0.20% |
| 2011-12-31 | CN¥1.96 Billion | +3.16% |
| 2010-12-31 | CN¥1.90 Billion | +547.64% |
| 2009-12-31 | CN¥294.09 Million | +42.53% |
| 2008-12-31 | CN¥206.34 Million | +45.75% |
| 2007-12-31 | CN¥141.57 Million | -- |